Company intelligence / Profile preview

Cellective BioTherapy, Inc.

Chapel Hill / Durham, North Carolina, United Statesrtp.org ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Cellective BioTherapy developed proprietary cellular and monoclonal antibody-based platforms targeting unique aspects of regulatory B cell biology to treat cancers, autoimmune conditions, and immunodeficiencies. The company focused on expanding human regulatory B cells ex vivo for autologous cellular immunotherapy as well as depleting pathogenic B cell subsets in vivo. No published clinical results are available; the company remained at an early/preclinical stage.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Cellular therapies (B cell-based)Monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

CBT-107

Preclinical

Beyond the preview

Go deeper on Cellective BioTherapy, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellective BioTherapy, Inc..

Explore the full profile